MISSISSAUGA, Ontario / Aug 20, 2025 / Business Wire / MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of Meghan Geary as the Company’s Senior Vice President of Operations, effective immediately.

With over 10 years experience in building scalable programs across SaaS and high-growth healthcare companies, Geary will oversee strategic operations, drive organization performance, and support MedX's continued growth trajectory.

"I'm excited to join MedX at such a pivotal stage of its journey," said Geary. "Throughout my career, I've focused on scaling programs that streamline processes and promote cross-functional alignment. I look forward to collaborating with the MedX team to optimize operations and ensure the Company is positioned for long-term success."

The Company’s CEO, John Gevisser added: “Meghan brings formidable experience to MedX at a time when we are scaling operations across different markets. Having previously worked closely with her, I understand what a vital asset to our team she is. Her ability to lead strategic programs, adjust and direct processes and improve organizational performance will play a central role in our next phase of growth. Meghan critically understands that our deep and dynamic image store is central to our AI and SaaS strategy.”

About MedX Health Corp.

MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy^® technology, integrated into the DermSecure^® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared for use in 38 countries including by Health Canada, the U.S. Food and Drug Administration (‘FDA’), the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX’s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy^®, and its secure, cloud-based patient management system, DermSecure^®. SIAscopy® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin’s surface. Visit: https//www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.